Development
Emergent BioSolutions Inc.
EBS
$6.22
-$0.02-0.32%
NYSE
| 12/31/2023 | 09/30/2023 | ||||
|---|---|---|---|---|---|
| Revenue | 2.26% | -19.76% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 2.26% | -19.76% | |||
| Cost of Revenue | 22.93% | -15.60% | |||
| Gross Profit | -38.94% | -26.92% | |||
| SG&A Expenses | 4.30% | -6.72% | |||
| Depreciation & Amortization | -0.61% | 1.24% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 15.90% | -12.22% | |||
| Operating Income | -326.05% | -177.27% | |||
| Income Before Tax | 79.50% | -6.49% | |||
| Income Tax Expenses | -100.00% | -116.78% | |||
| Earnings from Continuing Operations | 81.21% | 0.45% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 81.21% | 0.45% | |||
| EBIT | -326.05% | -177.27% | |||
| EBITDA | -246.67% | -68.35% | |||
| EPS Basic | 81.24% | 2.57% | |||
| Normalized Basic EPS | -75.09% | -103.91% | |||
| EPS Diluted | 81.24% | 2.60% | |||
| Normalized Diluted EPS | -75.09% | -103.91% | |||
| Average Basic Shares Outstanding | 0.19% | 2.17% | |||
| Average Diluted Shares Outstanding | 0.19% | 2.17% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||